What is the recommended cephalexin (Keflex) dosing for acute paronychia in adults, including adjustments for renal impairment and alternatives for severe penicillin or cephalosporin allergy?

Cephalexin (Keflex) Dosing for Acute Paronychia in Adults

For acute paronychia in adults, prescribe cephalexin 500 mg orally four times daily (every 6 hours) for 5-7 days, targeting the typical causative organisms Staphylococcus aureus and Streptococcus species. 1

Standard Dosing Regimen

The FDA-approved adult dosing for skin and soft tissue infections ranges from 1-4 grams daily in divided doses 1. For paronychia specifically:

• Standard dose: 500 mg every 6 hours (QID) orally
• Alternative: 500 mg every 12 hours (BID) may be equally effective for uncomplicated cases 2
• Duration: 5-7 days, extending treatment if infection hasn't improved 3

The IDSA guidelines for skin and soft tissue infections list cephalexin at 500 mg QID for MSSA infections, which aligns with paronychia treatment 3. While some studies demonstrate that twice-daily dosing achieves >97% efficacy for skin infections 2, the four-times-daily regimen remains the FDA-labeled standard and provides more consistent drug levels.

Renal Impairment Adjustments

Dose reduction is required when creatinine clearance falls below 30 mL/min 4:

• CrCl >30 mL/min: No adjustment needed
• CrCl <30 mL/min: Reduce dose proportionally based on degree of renal dysfunction
• Monitor serum creatinine or calculate creatinine clearance to guide adjustments 4

Cephalexin is 70-100% renally excreted unchanged within 6-8 hours, making dose adjustment critical in renal impairment 4.

Severe Penicillin/Cephalosporin Allergy Alternatives

For patients with documented severe penicillin allergy (anaphylaxis, Stevens-Johnson syndrome, or other severe cutaneous adverse reactions):

First-line alternatives:

• Clindamycin 300-450 mg orally four times daily 3
• Doxycycline 100 mg orally twice daily 3
• Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily 3

Important Caveats on Penicillin Allergy

Most patients with reported penicillin allergy can safely receive cephalexin. Less than 5% of patients labeled as penicillin-allergic have true persistent allergy 5. The cross-reactivity risk between penicillins and cephalosporins is substantially lower than historically believed:

• Cephalexin with non-aminopenicillin allergy: Extremely low cross-reactivity risk 5
• Cephalexin with aminopenicillin (amoxicillin/ampicillin) allergy: Slightly higher risk due to shared R1 side chain, but still generally safe 6, 7, 5
• First-generation cephalosporins overall: OR 4.8 for allergic reactions in penicillin-allergic patients 7

However, cefazolin has unique side chains and demonstrates very low cross-reactivity (0.8% in confirmed penicillin allergy) despite being first-generation 6. This suggests structural differences matter more than generation classification.

For low-risk penicillin allergy histories (non-anaphylactic reactions, distant history, vague symptoms), cephalexin can be used as first-line therapy 5. Reserve alternatives for patients with:

• Documented anaphylaxis to penicillins
• Recent severe reactions
• Confirmed aminopenicillin allergy with positive skin testing
• Multiple beta-lactam allergies

Clinical Pearls

• Paronychia typically involves MSSA and Streptococcus pyogenes, making cephalexin an excellent empiric choice
• Incision and drainage is often the primary treatment; antibiotics are adjunctive
• If MRSA is suspected (injection drug use, known colonization, treatment failure), switch to clindamycin or TMP-SMX 3
• Cephalexin achieves urinary concentrations 500-1000 mcg/mL, far exceeding MIC for typical pathogens, but tissue penetration is the relevant factor for paronychia 4
• The drug does not penetrate host cells, which contributes to its favorable safety profile 4